Company ProfilePremium

Bafna Pharmaceuticals Limited

Company Profile Analysis

Tickers: BAFNAPH.NS, 532989.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Bafna Pharmaceuticals Limited - Company showcase

Year Founded & Workforce

1981

363 Employees

Bafna Pharmaceuticals Limited logo

Bafna Pharmaceuticals Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Bafna Pharmaceuticals Limited Overview

Bafna Pharmaceuticals is a micro-cap, export-oriented Indian manufacturer of finished oral solid-dose formulations operating from a single Chennai plant at Grantlyon that holds UK-MHRA, EU-GMP, TGA (Australia), WHO-GMP and revised Schedule-M accreditations. The company runs two linked business models: contract manufacturing (CRAMS) for regulated-market marketing-authorisation holders in the UK, Europe and Australia, and sale of its own generics and branded generics into semi-regulated markets in Africa, Asia, CIS and Latin America. Its 336-formulation portfolio leans towards chronic "lifestyle" therapies — diabetes, CNS, cardiovascular and potent oncology/hormonal products — which made up about two-thirds of FY2025 revenue. The company emerged in 2020 from an NCLT-approved resolution process, after which SRJR Lifesciences LLP became promoter. FY2026 revenue was INR 1,506 M with EBITDA of INR 207 M. The stock has re-rated sharply, to above 140x trailing earnings, despite a weak Q1 FY2027.


The company's own description (Annual Report FY2025-26)

The FY2025-26 Annual Report describes Bafna as a 31-year-old listed pharmaceutical company engaged in the development, manufacture and global export of finished formulations. It says the company began as an institutional supplier, became a generic player, and is now a contract research and manufacturing services (CRAMS) partner. It exports branded generics and formulations to more than 20 countries across regulated and emerging markets. The report states that 100% of production, including deemed exports, goes to healthcare markets in Asia, Australia, West and East Africa, Europe, the UK and Latin America. The portfolio is stated at 336 product formulations covering antibiotics, anti-infectives, nutritional supplements, cardiovascular, diabetes, CNS and potent oncology therapies.

The report's stated vision is to become a global pharmaceutical company recognised for specialty generics, moving up the value chain under the banner "Wellness Beyond Boundaries". Its mission is to supply affordable, high-quality formulations from its accredited facility while maintaining cost leadership and regulatory standards.

Independent characterisation

In economic terms, Bafna is a sub-scale, capacity-led solid-oral contract manufacturer and dossier-led generic exporter. ICRA (Jan 2026) describes the model in two parts: contract manufacturing for regulated markets and sale of generics in semi-regulated or unregulated markets.

Revenue model: Nearly all revenue is product sales of manufactured finished dosage forms. There is no material subscription or licensing income. The "Out-Licensing" pillar of the Bafna 2.0 strategy is aspirational, and no licensing revenue has been disclosed. Other income (INR 47.6 M in FY2026) consists largely of export incentives, foreign-exchange gains and interest, and is non-core.

Value-chain position: Bafna is a downstream formulator. It buys APIs and excipients (part of them imported; FX outgo was INR 91.4 M in FY2026) and converts them into tablets and capsules. It also owns or prepares dossiers for product registrations in export markets. It does not manufacture APIs. Its in-house DSIR-recognised formulation R&D unit develops and scales up formulations and prepares registration dossiers.

Customer types: - Regulated-market marketing-authorisation holders and distributors. Named examples in ICRA rationales are Relonchem Limited (UK), Arrow Pharmaceuticals Pty Ltd (Australia, 2022) and Strides Pharma Science Limited.

  • Indian merchant exporters and pharma companies buying on a deemed-export basis, such as Tenshi Kaizen Private Limited and Cipla Limited (named in 2022).

  • Importers and distributors in emerging markets, for example Nigeria, the Philippines, Sri Lanka, Tanzania, Ethiopia and Ukraine.

Concentration: Customer concentration is extreme. ICRA reports that 78.4% of FY2025 sales came from the top 5 customers (elsewhere stated as "over 75%"). The top 5 products made up 56% of FY2025 revenue, and the top 3 molecules — Metformin, Fluoxetine and Lithium Carbonate — made up 45.0%.

End-markets: Demand comes from chronic-therapy generics in the UK and Australia (largely through NHS and PBS-type procurement via MAH customers) and from out-of-pocket or tender-driven markets in Africa and Asia. ICRA puts the lifestyle-disease share at 67.2% of FY2025 revenue (diabetology, CNS, pain management and others).

How the model makes money

Profitability depends on three factors: capacity utilisation at a single plant, product mix (high-margin "potent" and specialty orders versus commodity molecules such as metformin), and working-capital discipline. ICRA attributes the jump in operating margin to 15.1% in H1 FY2026 to a favourable product mix and some high-margin orders. That margin was not sustained: reported operating margin (excluding other income) fell back to 8.0% in Q3 FY2026 and 8.4% in Q4 FY2026, and Q1 FY2027 PAT almost disappeared. The business therefore behaves like a lumpy order-book manufacturer, not an annuity franchise.

Strategy

Stated strategy — "Bafna 2.0" (AR FY2025-26)

PillarStated initiatives
1. Geographic expansion & regulatory roadmapNorth America entry with diabetes and oncology formulations; scale in the UK, Europe, Australia, MENA, Sri Lanka, Philippines and CIS; file 6–8 new dossiers a year; begin regulatory groundwork in LATAM and CIS
2. Branded generics & strategic partnershipsScale high-margin branded generics in target regulated markets; alliances with tier-one regional distributors and local manufacturing partners to overcome trade barriers; asset-light out-licensing of proprietary products
3. Global visibility & trade engagementParticipation in CPHI Worldwide and similar events; use compliance and R&D credentials to win co-marketing and supply agreements
4. Digital reach & commercial digitalisationDigital B2B campaigns and virtual meetings; digital systems to track distributor pipelines and dossier requests

The Annual Report presents Bafna 2.0 as moving the company from a traditional manufacturer to an agile, globally recognised pharmaceutical company. It rests on three moves — shifting to high-value therapies, using strategic alliances and modernising commercial operations — organised in four pillars:

Initiatives executed in the last 24 months

InitiativeTimingDetail / status
Capsule capacity expansionFY2026375 M to 600 M units; utilisation about 30%
Dedicated granulation facilityFY2026Commissioned (CEO letter)
QC/QA laboratory upgradeFY2026Modern analytical instrumentation
High-containment potent-drug zonesFY2025–FY2026Expanded potent oncology and hormonal capability
Madhavaram unit divestmentBoard approval Aug 2024; completed Jun 2025INR 14.51 M sale; consolidation at Grantlyon
Solar PPAFY2026About 60% of plant power from solar
Regulatory filingsFY202651 new registrations; about 100 pending
MHRA re-inspectionFY2026"Satisfactorily completed"
Minimum public shareholding complianceMar–Apr 202513.30% promoter OFS
Sachet dosage linePipelineNot dated

Medium-term targets and guidance

EBITDA margin of at least 15%: (AR FY2026 financial highlights). FY2026 achieved 13.75%; Q1 FY2027 was well below this.

6–8 new dossier filings a year: - "Minimum-debt status" with prudent capex and working-capital control (AR FY2026). This sits uneasily with the rise in total debt to INR 374 M in FY2026.

Capex: of INR 200 M for FY2026 and INR 75 M for FY2027, funded from accruals and debt (ICRA, Jan 2026).

  • No numerical revenue guidance has been given publicly. The company holds no earnings calls and no investor-day transcripts exist.

ESG commitments

The company has a solar sourcing target of up to 60% of plant power (reported as achieved), water recycling and rainwater harvesting, a TNPCB-certified ETP, and CSR spending of INR 1.805 M in FY2026, which met the 2% obligation in full.

Products & Services

The company does not disclose product-level revenue, SKU-level pricing or launch dates. The catalog below is built from the FY2025-26 Annual Report's "Core Therapeutic Offerings" table and from ICRA product disclosures. Pricing is not publicly disclosed for any product. Revenue is earned on per-unit B2B supply prices or contract-manufacturing conversion fees.

Cardiovascular & hypertension (tablets)

MoleculeDescription / useTarget markets (AR FY2026)
TelmisartanAngiotensin-II receptor blocker (ARB) for hypertensionAsia, Africa, Central/South America, Australia, UK
LosartanARB for hypertension and diabetic nephropathySame
OlmesartanARB for hypertensionSame
AtorvastatinStatin for dyslipidaemiaSame
SimvastatinStatinSame
ClopidogrelAntiplatelet agentSame
LisinoprilACE inhibitorSame
Atenolol (listed as "Atenolyl")Beta-blockerSame
PropranololNon-selective beta-blockerSame
AmlodipineCalcium-channel blockerSame

Diabetes (tablets)

MoleculeDescriptionTarget markets
MetforminBiguanide; first-line type-2 diabetes therapy. One of the top 3 revenue molecules in FY2025Asia, Africa, Australia, UK
SitagliptinDPP-4 inhibitorSame
VildagliptinDPP-4 inhibitorSame
DapagliflozinSGLT2 inhibitorSame
EmpagliflozinSGLT2 inhibitorSame
GlimepirideSulfonylureaSame

The Bafna 2.0 strategy names advanced diabetes formulations as a candidate for North American entry. No US or Canadian filing has been disclosed.

Central nervous system (tablets, capsules)

MoleculeDescriptionTarget markets
FluoxetineSSRI antidepressant (capsules or tablets). One of the top 3 revenue molecules in FY2025UK, Asia, Africa, Central/South America
Lithium CarbonateMood stabiliser for bipolar disorder. One of the top 3 revenue molecules in FY2025Same (named by ICRA)
PregabalinNeuropathic pain / anticonvulsant (capsules)Same
GabapentinAnticonvulsant / neuropathic painSame
LevetiracetamAnti-epilepticSame
ClonazepamBenzodiazepine anticonvulsant / anxiolyticSame

Potent oncology & hormonal (tablets; high-containment manufacturing)

MoleculeDescriptionTarget markets
Prednisolone (incl. enteric-coated)Corticosteroid. The company says it was the first to launch generic Prednisolone EC tablets in the UK (launch year not disclosed)UK, Asia, Africa, Central/South America
TamoxifenSelective oestrogen receptor modulator (breast cancer)Same
LetrozoleAromatase inhibitor (breast cancer)Same
BicalutamideAnti-androgen (prostate cancer)Same
Finasteride5-alpha-reductase inhibitor (BPH / alopecia)Same

The FY2026 CEO letter states that capabilities in potent drug products were expanded during the year, supported by dedicated high-containment zones.

Anti-infectives (tablets)

MoleculeDescriptionTarget markets
LevofloxacinFluoroquinolone antibioticAsia, Africa, Central/South America
MoxifloxacinFluoroquinolone antibioticSame
AzithromycinMacrolide antibioticSame
LinezolidOxazolidinone antibioticSame

The company's heritage includes beta-lactam and non-beta-lactam products. Whether beta-lactam manufacturing continues at Grantlyon after the Madhavaram divestment is not publicly disclosed.

Nutritional supplements and other

The FY2026 Annual Report lists nutritional supplements among its therapy areas without naming products. Raricap (an oral haematinic, acquired from J&J in 2011) was sold to Strides in 2014. Strides acquired global rights to the brand, while Bafna reportedly retained some global (ex-India) rights at the time.

Services: CRAMS and specialty

OfferingDescriptionCustomers / markets
Contract manufacturingCustom solid-oral manufacture for MAH partnersUK, Australia, EU partners
Contract research / dossier filingsFormulation development and preparation of CTD dossiers for partnersSame
Specialty technologies (FR&D)Bi-layer tablets, modified-release solids, gastro-resistant and multi-layer coatings, ion-exchange-resin taste masking, stability-challenging molecules, potent/hormonal handlingPlatform capabilities; no named products
Pipeline: sachet oral dosageNew dosage-form line described as "coming soon"—

Registration footprint (AR FY2025-26)

The company reports 336 active formulations, "78+ global product registrations", active registrations in more than 20 countries, and about 100 applications pending. Fifty-one new registrations were obtained in FY2026:

Product Portfolio

CountryNew registrations FY2026

Philippines

20

Nigeria

13

Australia

5

Sri Lanka

4

Azerbaijan

3

Ghana

2

Tanzania

2

Bolivia

1

Georgia

1

Total

51

Financial Narrative

Basis.

  • FY2023–FY2026 P&L items come from the Annual Reports (Directors' Report tables and the FY2026 five-year summary).

  • FY2022 items and all balance-sheet and cash-flow lines come from S&P Global Market Intelligence (via StockAnalysis), which is standardised from the filings.

  • Ratios are analyst-computed unless noted.

  • Currency is INR million. EPS for FY2022–FY2024 is computed on 23,656,335 shares; FY2025 and FY2026 EPS are as reported.

Income statement

Revenue CAGR: 15.3% over FY2022–FY2026 (4 years); 9.3% over FY2023–FY2026 (3 years).

Commentary. The five years divide into three phases:

Post-resolution recovery (FY2022–FY2023): Revenue grew 35% to INR 1,154 M and EBITDA margin held at about 16%, as regulated-market CRAMS volumes ramped from a depressed base.

Volume-over-margin (FY2024–FY2025): FY2024 revenue rose a further 32%, but gross margin fell about 370 bp to 29.9% and EBITDA margin collapsed to 9.6%. This points to a shift towards lower-priced commodity chronic molecules (metformin, fluoxetine, lithium) and higher costs. FY2025 revenue then fell 4.3%. ICRA attributes the decline to machinery breakdowns and regulatory audits that disrupted production.

Mix-led margin recovery (FY2026): Revenue grew only 3.3%, but exports rose 31.3% while domestic and deemed-export sales fell about 25%. Gross margin recovered to 32.0% and EBITDA rose 49% to INR 207 M, a 13.75% margin. Management now targets an EBITDA margin of at least 15%.

The FY2026 improvement was front-loaded. ICRA's 15.1% H1 margin compares with reported operating margins (excluding other income) of 7.97% in Q3 and 8.40% in Q4. A rising share of other income (INR 47.6 M, 23% of EBITDA) also flattered the result.

Quarterly trajectory (last nine quarters)

Sources: Capital Market / Business Standard result summaries and company filings. Q1 FY2027 sales are derived from the reported 23.22% year-on-year decline versus Q1 FY2026 sales of INR 34.62 crore. Reported operating margins (excluding other income) were:

  • 9.42% in Q2 FY2025, 9.25% in Q3 FY2025 and 7.96% in Q4 FY2025;

  • 12.04% in Q2 FY2026, 7.97% in Q3 FY2026 and 8.40% in Q4 FY2026.

Q1 FY2027 is the weakest quarter in the series. Trailing-twelve-month PAT has fallen to about INR 77.9 M (INR 7.79 crore). The cause of the revenue decline (order timing, plant shutdown, customer destocking or audit) has not been explained in any public commentary found.

Balance sheet

Commentary. Capex of INR 155.8 M in FY2024, INR 218.6 M in FY2025 and INR 249.0 M in FY2026 (about 41% of three-year revenue on a cumulative basis) more than doubled net PP&E, from INR 388 M to INR 849 M. The spend went on granulation, capsule capacity (375 M to 600 M units), QC/QA laboratory upgrades and high-containment zones. It was funded mainly by debt: total debt rose 3.4x from FY2022. The near-term debt profile has worsened. The current portion of long-term debt jumped to INR 196.5 M at FY2026 from INR 56.0 M at FY2025, and cash was only INR 20.3 M, so refinancing or accrual-funded repayment in FY2027 is a monitorable. Gearing remains moderate at 0.39x debt to S&P equity, or about 0.54x on the company's net worth basis.

Cash flow

Source: S&P Global via StockAnalysis.

Cumulative five-year free cash flow is negative INR 149 M. The business has not yet self-funded its capacity build. FY2025's strong operating cash flow (INR 221 M) came from a working-capital release: receivables fell by INR 55 M as collections improved, which is consistent with ICRA's note that working-capital intensity fell to 30.9% from above 40%. That release partly reversed in FY2026. ICRA had guided capex of INR 200 M for FY2026 and INR 75 M for FY2027; the actual FY2026 figure (INR 249 M) exceeded guidance. If FY2027 capex normalises to about INR 75 M, positive free cash flow becomes plausible, provided operating cash flow recovers from the weak Q1.

Ratios

Basis. ROE, ROA, ROIC, ROCE, the liquidity ratios, D/E and turnover ratios are from S&P Global. Coverage ratios, net debt/EBITDA and the cash conversion cycle are analyst-computed from year-end balances and S&P cost of revenue. The company-reported return on net worth was 6.86% for FY2025 and 15.31% for FY2026. ICRA-adjusted ratios are: Total debt/OPBDITA of 1.7x (FY2024), 2.1x (FY2025) and 1.6x (H1 FY2026); interest coverage of 6.1x, 5.0x and 6.0x for the same periods.

Commentary. Returns peaked in FY2023 (ROIC 14.2%), troughed in FY2025 (6.5%) and recovered only partly in FY2026 (8.8%). This is close to or below a plausible INR cost of capital for a BB+ rated micro-cap. The cash conversion cycle of 90–100 days is typical for an export CDMO with credit terms to MAH customers. Overdue export receivables of about INR 12.3 M beyond RBI realisation timelines (auditor's emphasis of matter, Q1 FY2026) show some collection risk in semi-regulated markets. Interest coverage has roughly halved since FY2023 as debt-funded capex built up.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Segment Margins & Growth (%)

Segment (Ind AS 108)FY2024FY2025FY2026

Pharmaceutical formulations — revenue (INR Mn)

1,524.661,458.571,506.17

YoY growth (%)

32.18-4.333.26

Share of total revenue (%)

100100100

Segment PBT before exceptional (INR Mn)

73.4862.08109.70

Segment PBT margin (%)

4.824.267.28

Disclosure Details

DisclosureValuePeriodSource

Lifestyle-disease therapies, share of revenue

67.1%

FY2022

ICRA, Nov 2022

Lifestyle-disease therapies, share of revenue

67.2%

FY2025

ICRA, Jan 2026

Top 3 products (Metformin, Fluoxetine, Lithium Carbonate), share of revenue

45.0%

FY2025

ICRA, Jan 2026

Top 5 products, share of revenue

56%

FY2025

ICRA, Jan 2026

Top 5 customers, share of sales

78.4%

FY2025

ICRA, Jan 2026

Export sales

INR 958.10 M (63.6% of revenue)

FY2026

AR FY2025-26

Export sales

INR 729.78 M (50.0% of revenue)

FY2025

AR FY2025-26

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Mn)

851.401,153.501,524.661,458.571,506.17

Revenue growth (%)

19.5535.4832.18-4.333.26

Other income (INR Mn)

16.9832.7335.2227.4247.56

Total income (INR Mn)

868.381,186.221,559.881,485.991,553.73

Gross profit (INR Mn)

338.60387.60455.59427.96481.34

Gross margin (%)

39.7733.6029.8829.3431.96

EBITDA incl. other income (INR Mn)

136.60189.88146.34139.19207.04

EBITDA margin on revenue (%)

16.0416.469.609.5413.75

Depreciation & amortisation (INR Mn)

54.9353.3449.9548.9060.73

EBIT (INR Mn)

81.67136.5496.3890.29146.31

EBIT margin (%)

9.5911.846.326.199.71

Finance cost (INR Mn)

5.2420.3822.9027.3136.61

PBT before exceptional items (INR Mn)

73.62116.1673.4862.08109.70

Exceptional items (INR Mn)

000-21.460

Net profit / PAT (INR Mn)

52.16113.3873.4841.53111.00

Net margin (%)

6.139.834.822.857.37

EPS basic (INR)

2.204.793.111.764.69

EPS diluted (INR)

2.204.793.111.764.69

Dividend per share (INR)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Financials

MetricQ1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Sales (INR Cr)

33.2940.3233.1939.0634.6235.4738.2942.2426.58

PAT (INR Cr)

-0.722.620.951.313.393.121.842.750.08

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Mn)

901.451,296.001,477.001,531.001,755.00

Cash & equivalents (INR Mn)

1.7378.0913.9634.3320.25

Trade & other receivables (INR Mn)

148.76412.03454.77401.97440.07

Inventory (INR Mn)

202.81222.20296.42280.86289.03

Property, plant & equipment (INR Mn)

388.46402.30507.07660.93849.24

Goodwill & intangibles (INR Mn)

015.0017.7000

Short-term debt incl. current LTD (INR Mn)

57.43144.90136.36141.70196.51

Long-term debt (INR Mn)

53.1784.33107.53140.29177.82

Total debt (INR Mn)

110.59229.24243.89281.99374.33

Net debt (INR Mn)

108.86151.15229.93247.66354.09

Accounts payable (INR Mn)

124.05284.61354.22309.45312.86

Shareholders' equity, S&P basis (INR Mn)

619.64734.55808.39848.07961.50

Net worth, company basis (INR Mn)

349.80464.70538.60578.30691.60

Working capital (INR Mn)

288.67408.35396.88343.27324.63

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Mn)

97.2849.5394.85221.36153.71

Capital expenditure (INR Mn)

75.4167.19155.78218.60249.03

Free cash flow (INR Mn)

21.87-17.66-60.932.76-95.32

Change in working capital (INR Mn)

-7.95-144.20-52.8075.49-56.05

Net debt issued / (repaid) (INR Mn)

-47.27118.6514.6538.0992.35

Cash interest paid (INR Mn)

0.8816.8723.1127.4636.12

Dividends paid (INR Mn)

00000

Share buybacks (INR Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE, S&P equity basis (%)

8.7916.749.535.0112.27

ROA (%)

4.706.703.312.894.02

ROIC (%)

9.2514.247.636.518.76

ROCE (%)

9.7014.207.806.908.90

Current ratio (x)

2.311.881.731.631.57

Quick ratio (x)

0.681.050.870.840.80

Debt / equity (x)

0.180.310.300.330.39

Net debt / EBITDA, company EBITDA (x)

0.800.801.571.781.71

EBITDA / interest (x)

26.079.326.395.105.66

EBIT / interest (x)

15.596.704.213.314.00

Asset turnover (x)

0.961.051.100.970.92

Inventory turnover (x)

2.893.624.143.583.61

Receivable days (DSO)

63.8130.4108.9100.6106.6

Inventory days (DIO)

143.6105.3100.899.1102.9

Payable days (DPO)

87.8134.9120.5109.2111.4

Cash conversion cycle (days)

119.6100.889.290.598.1

Revenue by Region and Region Margins & Growth (%)

MetricFY2023FY2024FY2025FY2026

Foreign exchange earnings (INR Mn)

885.091,030.72729.29928.56

FX earnings as % of revenue

76.7367.6050.0061.65

FX earnings growth (%)

016.45-29.2527.32

Foreign exchange outgo (INR Mn)

90.61120.7833.2591.36

Revenue by Region and Region Margins & Growth (%) (FY2025–FY2026)

MetricFY2025FY2026

Direct export sales (INR Mn)

729.78958.10

Domestic incl. deemed-export sales (INR Mn)

728.79548.07

Direct export growth (%)

031.29

Domestic / deemed growth (%)

0-24.80

Direct exports as % of revenue

50.0363.61

Region Overview

RegionMarkets namedRegulatory characterDirection

UK & Europe

UK; EU partners

Regulated (MHRA, EU-GMP)

Core CRAMS market; MHRA audit satisfactorily completed in FY2026

Australasia

Australia; New Zealand flagged as potential

Regulated (TGA)

5 new registrations in FY2026

Africa

Nigeria, Kenya, Uganda, Ghana, Ethiopia, Rwanda, Tanzania, Madagascar, DRC/Congo, Mauritius

Semi-regulated / emerging

Fast-growing registration base (Nigeria 13 new in FY2026)

Asia

Philippines, Sri Lanka, Nepal

Emerging

Philippines 20 new registrations in FY2026, the largest single market for new filings

CIS

Ukraine, Azerbaijan, Georgia; Russia and Uzbekistan named as targets

Emerging

4 new registrations in FY2026

Latin America

Bolivia, Guatemala, Peru, Nicaragua; Brazil, Mexico and Chile as future targets

Emerging

Groundwork stage

MENA

UAE, Saudi Arabia, Egypt as potential markets

Not yet active

Future

North America

Targeted for diabetes and oncology launches

Highly regulated (US FDA)

No filing disclosed

Share Price and Market Valuation

MetricMar2022Mar2023Mar2024Mar2025Mar2026Oct2026

Closing price (INR)

126.6582.0078.3574.80109.34461.35

Market cap (INR Mn)

2,9961,9401,8531,7692,58710,914

Valuation Multiples (x) and Market Valuation

MetricFY2022FY2023FY2024FY2025FY2026Current

P/E (x)

57.4417.1125.2342.6123.30142.21

EV/EBITDA (x)

25.0712.3015.7416.4317.4896.76

EV/Sales (x)

3.571.821.271.331.937.90

P/B (x)

4.842.642.292.092.6911.35

Enterprise value (INR Mn)

3,0422,1041,9411,9452,90811,268

Credit Ratings

AgencyInstrumentRating / outlookDate

ICRA

Long-term term loans (INR 258.7 M)

[ICRA]BB+ (Positive)

23 Jan 2026

ICRA

Long-term cash credit (INR 200.0 M)

[ICRA]BB+ (Positive)

23 Jan 2026

ICRA

Long-term unallocated (INR 41.3 M)

[ICRA]BB+ (Positive)

23 Jan 2026

ICRA

Short-term letter of credit (INR 50.0 M, interchangeable)

[ICRA]A4+

23 Jan 2026

Moody's / S&P / Fitch

—

Not rated

—

Analyst Conclusions

Management guidance

The only quantified targets are:

  • an EBITDA margin of at least 15% (versus 13.75% in FY2026);

  • 6–8 dossier filings a year;

  • capex of INR 75 M in FY2027 (ICRA);

  • "minimum-debt status".

There is no revenue guidance and there are no earnings calls. Q2 FY2027 results are due in the first half of November 2026, after the trading-window closure that began on 1 Oct 2026.

Consensus growth expectations

Not available, because the stock has no institutional coverage.

Bull case

  1. Operating leverage on a capex cycle that is now complete. Net PP&E rose from INR 388 M to INR 849 M over FY2022–FY2026. Capsules are only about 30% utilised and tablets about 65%. If capsules reach 60% utilisation, mostly incremental gross margin with capex falling to about INR 75 M, revenue could grow 20–30% and free cash flow could turn decisively positive.

  2. Mix shift to regulated and potent products. Exports rose 31% in FY2026, potent capacity has expanded and 51 registrations were won in one year. Sustaining the H1 FY2026 margin profile (15% EBITDA per ICRA) would make the at-least-15% target credible. On a normalised basis — INR 1,800 M revenue at a 15% margin — EBITDA would be about INR 270 M.

  3. Credit and governance normalisation. A Positive ICRA outlook, MPS compliance, a cleaner board and audit-trail remediation could bring an investment-grade rating, lower interest cost and broader institutional ownership.

Bear case

  1. The FY2026 profit spike looks lumpy, not structural. Quarterly operating margins fell from 12.0% (Q2) to about 8% (Q3–Q4). Q1 FY2027 PAT of INR 0.8 M on revenue down 23% suggests the H1 FY2026 high-margin orders were one-offs. TTM PAT has already fallen to about INR 78 M.

  2. Concentration and single-site fragility. With 78% of revenue from five customers and 45% from three commodity molecules, a single customer loss, MHRA observation or machinery failure (as in FY2025) can erase a year's profit. There is no second plant to absorb disruption.

  3. Valuation is untethered from fundamentals. At about 142x trailing earnings, about 97x EV/EBITDA and 11x book, the equity values Bafna at about INR 11.3 bn. That is close to 10x Lincoln Pharma on a revenue-adjusted basis, for a business with lower margins, negative cumulative free cash flow and rising debt. Exchange surveillance, thin float and circuit-bound trading mean exit liquidity may vanish on any disappointment.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableTimingWhat to watch
Q2 FY2027 resultsNov 2026Whether revenue recovers above INR 350 M per quarter and operating margin above 10%
H1 FY2027 balance sheetNov 2026Refinancing of INR 197 M current maturities; cash; receivable days
ICRA surveillanceAround Jan 2027Positive outlook converted to upgrade, or reverted to Stable
GST / IGST litigation in the Madras HCOngoingAny adverse order on the INR 56.7 M demands
Board compositionNear termAppointment of a third independent director to restore headroom
Capsule utilisation and new customersFY2027Any named CRAMS contract or out-licensing deal
North America / LATAM / CIS filingsFY2027First US-facing filing or dossier submission
Promoter actionsOngoingAny further SRJR stake sale, preferential issue or corporate restructuring that could explain the re-rating
Price-surveillance actionsOngoingASM/GSM framework changes; exchange clarifications
Tax normalisationFY2027–FY2028Exhaustion of loss carry-forwards

Analyst verdict

Bafna Pharmaceuticals is a genuine turnaround story at the operating level. Six years after an NCLT-supervised resolution, it runs a single Chennai solid-oral plant with UK-MHRA, EU-GMP and TGA accreditations — credentials that many larger Indian peers lack. It has rebuilt revenue to INR 1.5 bn, doubled its fixed-asset base, added high-containment potent capacity and, in FY2026, delivered its best post-resolution profit of INR 111 M on a 13.75% EBITDA margin. Its export pivot (+31%), 51 new registrations and a Positive ICRA outlook show real progress.

The evidence does not support a structurally higher-quality business, however. FY2026 profitability was concentrated in the first half: ICRA's 15.1% H1 margin gave way to roughly 8% operating margins in Q3 and Q4. Q1 FY2027 then delivered near-zero profit on a 23% revenue decline. The business remains exposed to five customers (78% of sales), three commodity molecules (45%) and one plant. Free cash flow has been negative cumulatively over five years, and debt has more than tripled. Governance has improved but repeatedly falls short of LODR requirements, and the board now has only two independent directors.

Against this backdrop, the market capitalisation has risen about fourfold since March 2026 to about INR 1,090 crore, with no disclosed corporate event. The company itself told the exchanges it was unaware of any trigger. That implies about 142x trailing earnings and about 97x EV/EBITDA, multiples that price in successful execution of Bafna 2.0 several years ahead.

Verdict: the business deserves cautious interest, but the current valuation does not. On fundamentals the stock screens as substantially overvalued, with a skewed risk–reward and impaired liquidity. A constructive stance would require two or more consecutive quarters of revenue above INR 400 M at an EBITDA margin of 15% or more, positive free cash flow, a named new regulated-market contract and restoration of independent-director headroom. Until then, Bafna is a show-me turnaround trading at a speculative price.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundCompensation (latest disclosed)

Bafna Mahaveer Chand

Chief Executive Officer; founder and promoter-group member

Founder since 1981; CEO since 10 Sep 2020 (earlier MD); re-appointed as CEO Sep 2025

More than 30 years in pharma manufacturing; was the resolution applicant under the 2019–20 NCLT process

FY2024 remuneration was 22.99x the median employee, up 100% year on year (AR FY2023-24)

Dr. Melagiri Sridhar

Chief Financial Officer

Since 27 May 2017 (MCA data)

Not publicly detailed

FY2024: 4.98x median, +14%

A. Mohanachandran

Company Secretary & Compliance Officer

Since 29 May 2024 (succeeded Vishnu Vasudeva Kuppa)

Not publicly detailed

—

“—” = not publicly disclosed.

Board of Directors

NameCategoryAppointed / tenureAgeEducation / prior roles

Ms. Ravichandran Chitra (DIN 07749125)

Chairperson, Independent Director

Second term from 12 Nov 2025

—

B.Com; PGDPMIR (Madras School of Social Work); 30+ years in HR, training and governance

Mr. Palamadai Krishnan Sundaresan (DIN 06954189)

Independent Director; Chair of Audit Committee and NRC from 23 Jun 2026

Second term from 19 Sep 2025

—

CMA and CS; 40+ years in corporate finance, FEMA, M&A and restructuring

Ms. Shanmugam Hemalatha (DIN 02714329)

Whole-Time Director (commercial, strategy, finance)

Board since 10 Sep 2020; re-appointed for 5 years to 9 Sep 2028

51 (born 19 Apr 1975)

B.Com, CS (Inter), ICWA (Inter); 20+ years at the company

Mr. Vinayak Dinesh Dendukuri (DIN 07601309)

Whole-Time Director (Quality)

26 Jun 2023 to 24 Jun 2028

—

BS Biotechnology (RIT); MS (University of Rochester); co-founder of NOVICK Biosciences; ex-Quintiles drug-safety scientist; research roles at Sanofi Pasteur and GSK (USA)

Mr. Upendar Mekala Reddy (DIN 08898174)

Non-Executive, Non-Independent (promoter nominee; Designated Partner, SRJR Lifesciences LLP)

Since 26 Jun 2023; re-appointed by rotation at 31st AGM

44 (born 10 Dec 1981)

MBA Finance (IIM Kozhikode); B.Tech CSE (JNTU); FRM; iLabs Group; ex-Edelweiss VP, IL&FS Financial Services, L&T Infrastructure Finance

Ms. Akila Chintalapati Raju (DIN 07590312)

Non-Executive, Non-Independent

On board by FY2023

—

LL.M. (NYU); former in-house counsel at Strides Shasun (Australia set-up); litigation practice in Hyderabad

“—” = not publicly disclosed.

Major Shareholders

ShareholderCategorySharesStake (%)As of

SRJR Lifesciences LLP

Promoter

17,640,01674.57

Mar–Jun 2026

P. Paras Bafna

Promoter group

50,0000.21

Jun 2026

Navin Bafna

Promoter group

42,0150.18

Jun 2026

Mahaveer Chand Bafna

Promoter group

6,3380.03

Jun 2026

Amri Bai Bafna

Promoter group

1,9890.01

Jun 2026

Sasikala Bafna

Promoter group

1,8440.01

Jun 2026

M7 Global Fund PCC – Aerion

FPI

760,0593.21

2026 (Bajaj Finserv data)

M7 Global Fund PCC – Cell Dewcap Fund

FPI

737,1583.122,026

Zeal Global Opportunities Fund

FPI

712,5863.012,026

Alpana Mundra

Individual (public)

not stated

2.91

Jul 2025 (MarketsMojo)

Governance Overview

MetricDec2020Dec2021Sep2023Sep2024Mar2025Jun2026

Promoter holding (%)

92.6490.4288.7488.3075.0075.00

FII holding (%)

00008.539.34

Competitive Landscape

Key Competitors

CompetitorArena of overlapScale / metrics (latest available)Relative positioning vs. Bafna

Lincoln Pharmaceuticals

Emerging-market branded generics exports (Africa, LATAM), domestic

TTM revenue INR 694 crore; PAT INR 96.45 crore; net margin 13.1%; ROE 13.1%; market cap INR 1,183 crore; P/E 12.3 (Value Research, 25 Sep 2026)

About 5x Bafna's revenue at a similar market cap

Caplin Point Laboratories

LATAM / emerging-market generics; US injectables

TTM revenue INR 2,287 crore; PAT INR 678 crore; net margin 28.1%; ROE 19.7%; P/E 28.6 (Value Research, 9 Oct 2026)

Best-in-class emerging-market model; about 16x Bafna's revenue

Shilpa Medicare

Oncology / potent formulations; CDMO

TTM revenue INR 1,682 crore; PAT INR 273.5 crore; ROE 11.2%; P/E 66.7

Integrated API-to-formulation potent player

Strides Pharma Science

UK/Australia generics; emerging markets

—

Both customer and competitor; vastly larger

Marksans Pharma

UK and Australia OTC/Rx generics (owns UK MAH businesses)

—

Direct competitor in UK solid orals with owned front-ends

Kilitch Drugs (India)

Emerging-market (Africa) formulations exporter

Market cap INR 677.6 crore; P/E 22.5; ROE 10.8% (Motilal Oswal, 6 Aug 2026)

Closest micro-cap analogue

Jenburkt Pharmaceuticals

Branded formulations (India and exports)

Market cap INR 510.6 crore; P/E 14.7; ROE 17.6%

Higher ROE, lower valuation

Influx Healthtech

Contract manufacturing (nutraceutical/pharma)

Market cap INR 672.5 crore; P/E 32.7; ROE 20.4%

CMO peer

Amanta Healthcare

Contract manufacturing (parenterals) and exports

Market cap INR 658.3 crore; P/E 44.9; ROE 6.8%

CMO peer

Medicamen Biotech

Oncology / potent oral formulations for export

—

Overlap in potent oncology

Peer Comparison FY2026

MetricBafna PharmaLincoln PharmaCaplin PointShilpa Medicare

TTM revenue (INR Cr)

1436942,2871,682

TTM net profit (INR Cr)

7.7996.45678.07273.51

Net margin (%)

5.2413.0928.1016.19

ROE (%)

8.3113.0919.7311.15

P/E (x)

12712.328.666.7

P/B (x)

10.31.55.27.4

R&D intensity (%)

1.73 (FY2026)

———

Revenue growth FY2026 (%)

3.26———

Company Snapshot

$17.4M

Revenue

363

Employees

1981

Founded

Chennai, India

Headquarters

SWOT Analysis

Strengths

  • Tier-1 accreditations: UK-MHRA, EU-GMP, TGA and WHO-GMP at Grantlyon (AR FY2026). The MHRA audit was "satisfactorily completed" in FY2026.
  • Profit recovery in FY2026: EBITDA of INR 207.0 M (+48.7%), margin of 13.75% (from 9.54%), PAT of INR 111.0 M (+167%) (AR FY2026).
  • Export momentum: direct exports of INR 958.1 M (+31.3%), 63.6% of revenue (AR FY2026).
  • Registration pipeline: 51 new registrations in FY2026 and about 100 pending (AR FY2026).
  • Capacity headroom: capsules at about 30% and tablets at about 65% utilisation (AR FY2026), so growth needs limited further capex.
  • Positive credit trajectory: ICRA outlook revised to Positive on 23 Jan 2026; rated limits raised to INR 500 M.
  • Clean promoter holding: nil pledges (FY2026 declarations), with the promoter holding a stable 75%.

Weaknesses

  • Customer concentration: 78.4% of FY2025 sales from the top 5 customers (ICRA).
  • Product concentration: 45.0% of FY2025 revenue from Metformin, Fluoxetine and Lithium Carbonate (ICRA).
  • Scale: FY2026 revenue of INR 1,506 M, which ICRA describes as "modest scale", limiting economies of scale.
  • Negative free cash flow: cumulative five-year FCF of -INR 149 M; FY2026 FCF of -INR 95.3 M (S&P).
  • Low R&D intensity: 1.73% of revenue in FY2026 (AR FY2026).
  • Governance and compliance record: ten secretarial or audit observations across FY2024–FY2026, including the MPS breach, late RPT ratification, late disclosure of the GST order and audit-trail deficiencies (secretarial audit reports and auditor's report).
  • Earnings volatility: Q1 FY2027 PAT of INR 0.8 M against INR 33.9 M in Q1 FY2026.

Opportunities

  • Monetising idle capsule capacity (225 M units added in FY2026) for UK/EU CRAMS customers.
  • Potent oncology and hormonal products (Tamoxifen, Letrozole, Bicalutamide, Prednisolone EC), with first-to-market precedent in the UK.
  • New geographies: CIS and LATAM groundwork; Philippines (20 registrations) and Nigeria (13) can be scaled.
  • Branded generics in emerging markets — a higher-margin pillar of Bafna 2.0.
  • Sachet line — a new dosage form now in the pipeline.
  • ICRA upgrade path: sustained scale and margins could lift the rating to investment grade, lowering borrowing costs.

Threats

  • Tax and indirect-tax disputes: GST demands of INR 23.55 M and INR 33.11 M; the IGST refund recovery order of 25 Dec 2025 is stayed but unresolved.
  • Regulatory inspections: FY2025 revenue fell 4.6% (ICRA basis) partly because of audits. A single adverse MHRA or TGA finding could halt regulated-market supply from the only plant.
  • Customer loss: any one of the top 5 customers leaving could remove 10–20% of revenue. Domestic and deemed sales already fell 24.8% in FY2026.
  • FX and collection risk: INR 12.3 M of export receivables overdue beyond RBI limits (Q1 FY2026 review report).
  • Valuation and liquidity risk: about 142x trailing P/E, a 2% daily price band pattern and exchange surveillance notices (Mar–Apr 2026). These raise drawdown risk for minority holders.
  • Rising refinancing need: current maturities of long-term debt of INR 196.5 M against cash of INR 20.3 M at FY2026 (S&P).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
31 Mar 2025Independent Director Krishna Yeachuri resigns (NRC chair)Committee compliance gap follows
2 Apr 2025MPS compliance letter: promoter holding cut to 75% after the 27–28 Mar OFSEnds a multi-year LODR breach; free float rises
2 Apr 2025ICRA reaffirms BB+ (Stable)/A4+Credit stability
28 Apr 2025"Emerging Company of the Year in Healthcare" award (MSME Global Platinum Business Excellence Awards)Reputational
20 May 2025NRC reconstituted with the board chairperson as NRC chairLater flagged as a Reg 19(2) non-compliance
26 May 2025Q4/FY2025 results: FY2025 sales INR 1,458.6 M (-4.3%), PAT INR 41.5 M (-44%) after exceptional write-offs of INR 21.5 MTrough year
24–25 Jun 2025P K Sundaresan retires as ID; Navin Kumar inducted; committees reconstitutedBoard churn
30 Jun 2025Madhavaram unit sale to Navron Pharma completed for INR 14.51 MSingle-site consolidation
12 Aug 2025Q1 FY2026: sales INR 346.2 M (+4%), PAT INR 33.9 M versus a loss of INR 7.2 M. Auditor's emphasis of matter on INR 12.3 M overdue export receivables, INR 4.5 M income-tax refund adjustment (writ filed) and MPS penaltiesMargin inflection; compliance flags
12 Aug 2025NRC reconstituted under Navin KumarCompliance cured
19 Sep 202530th AGM: CEO re-appointed; P K Sundaresan re-appointed (second term); Navin Kumar appointed IDLeadership continuity
11 Nov 2025Q2 FY2026: sales INR 354.7 M (-12%), PAT INR 31.2 M (+19%), OPM 12.0%Mix-led margins despite lower sales
12 Nov 2025R Chitra second term as ID beginsGovernance continuity
25 Dec 2025GST & Central Excise order (Chennai North) for recovery of IGST refunds with interest and penalty; Madras HC interim stay obtainedContingent liability; disclosure later found to be late
23 Jan 2026ICRA reaffirms BB+/A4+, outlook revised to Positive; limits raised to INR 500 MCredit-positive
11 Feb 2026Q3 FY2026: sales INR 382.9 M (+15%), PAT INR 18.4 M (+94% YoY, -41% QoQ), OPM 7.97%. GST demands of INR 23.55 M and INR 33.11 M disclosedMargin normalisation; tax overhang
23–24 Mar 2026Exchanges seek clarification on price movement; company says it is unaware of any triggering eventSpeculative interest
27 Mar 2026K.S. Rao & Co. (internal) and N. Sivashankaran & Co. (cost) appointed for FY2027Routine
13–15 Apr 2026Further exchange notices on significant price movementSurveillance
29 May 2026FY2026 results: revenue INR 1,506.2 M (+3.3%), EBITDA INR 207.0 M (+48.7%), PAT INR 111.0 M (+167%), EPS INR 4.69; Q4 sales INR 422.4 M (+8%)Best profit year since resolution
22 Jun 2026Navin Kumar retires as ID; P K Sundaresan takes Audit and NRC chairsBoard down to two IDs
Jul 2026Stock makes new 52-week highs (INR 233.58 on 21 Jul)Momentum
11 Aug 2026Q1 FY2027: revenue about INR 265.8 M (-23% YoY), PAT INR 0.8 M (-98%)Sharp earnings miss against FY2026 run-rate
19 Aug 2026FY2026 Annual Report published; Bafna 2.0 strategy and EBITDA target of at least 15% articulatedStrategy disclosure
11 Sep 202631st AGM: accounts adopted; Upendar Mekala Reddy re-appointed; cost auditor fee ratifiedRoutine
26 Sep 2026Trading window closed from 1 Oct 2026 ahead of Q2 FY2027 resultsQ2 results due (likely early-to-mid Nov 2026)
16 Oct 2026Share price INR 461.35, market cap about INR 1,091 crore; trailing P/E about 142xValuation divorced from fundamentals

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 851.4 Mn in FY2022 to INR 1,506.2 Mn in FY2026.
Bafna Pharmaceuticals Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations851.41,153.51,524.71,458.61,506.2
Gross profit338.6387.6455.6428481.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Bafna Pharmaceuticals Annual Report FY2025-26 (NSE filing BAFNAPH_19082026211340, 19 Aug 2026)
  2. Bafna Pharmaceuticals Annual Report FY2023-24 (BSE filing, 2 Sep 2024)
  3. Outcome of Board Meeting and unaudited results for Q1 FY2026 (NSE filing BAFNAPH_12082025170554, 12 Aug 2025) with the Brahmayya & Co. limited review report
  4. ICRA rating rationales: 30 Nov 2022 and 23 Jan 2026
  5. CRISIL rating rationale, 28 Jun 2019; CRISIL advisory, 27 Feb 2020
  6. Exchange disclosures: MPS compliance letter (9 Apr 2025); SAST/PIT disclosures (31 Mar 2025); handover to resolution applicant (16 Mar 2020); board outcomes of 13 Feb 2020, 25 Jun 2020 and 10 Sep 2020; AGM outcome (19 Sep 2025); Reg 30 disclosure (19 Sep 2025)
  7. Strides Arcolab press release, 21 Jul 2014; BioSpectrum India and The Pharma Letter, Jul 2014
  8. Business Standard / Capital Market result summaries (May 2025, Nov 2025, Feb 2026, May 2026); Arihant Capital (CMOTS) data
  9. S&P Global Market Intelligence via StockAnalysis.com (income statement, balance sheet, cash flow, ratios; accessed Oct 2026)
  10. Screener.in, Trendlyne, Value Research, Motilal Oswal, Bajaj Finserv, Emkay Global, Upstox, Univest, ScanX, MarketsMojo, Equentis, Kotak Neo, Anand Rathi (market data, shareholding, Q1 FY2027 summary)
  11. Pharmexcil Handbook (Jun 2025) and Pharmexcil statements reported by Outlook Business / DT Next (Apr 2026); IndiaMedToday (Feb 2026)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.